Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Grubmüller B, et al. Among authors: pfaff s. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19. Eur J Nucl Med Mol Imaging. 2019. PMID: 30569186 Free PMC article.
PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact.
Grubmüller B, Baltzer P, Hartenbach S, D'Andrea D, Helbich TH, Haug AR, Goldner GM, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroteran-Infante N, Grahovac M, Babich J, Seitz C, Kramer G, Susani M, Mazal P, Kenner L, Shariat SF, Hacker M, Hartenbach M. Grubmüller B, et al. Among authors: pfaff s. Clin Cancer Res. 2018 Dec 15;24(24):6300-6307. doi: 10.1158/1078-0432.CCR-18-0768. Epub 2018 Aug 23. Clin Cancer Res. 2018. PMID: 30139879
Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy.
Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M. Abufaraj M, et al. Among authors: pfaff s. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2169-2177. doi: 10.1007/s00259-019-04361-0. Epub 2019 Jun 29. Eur J Nucl Med Mol Imaging. 2019. PMID: 31254037 Free PMC article. Clinical Trial.
Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M. Grubmüller B, et al. Among authors: pfaff s. Prostate. 2020 Jan;80(1):74-82. doi: 10.1002/pros.23919. Epub 2019 Oct 15. Prostate. 2020. PMID: 31614001
Microfluidic 68Ga-labeling: a proof of principle study.
Pfaff S , Philippe C , Pichler V , Hacker M , Mitterhauser M , Wadsak W . Pfaff S , et al. Dalton Trans. 2018 May 1;47(17):5997-6004. doi: 10.1039/c8dt00158h. Dalton Trans. 2018. PMID: 29664103
An Overview of PET Radiochemistry, Part 1: The Covalent Labels 18F, 11C, and 13N.
Pichler V, Berroterán-Infante N, Philippe C, Vraka C, Klebermass EM, Balber T, Pfaff S, Nics L, Mitterhauser M, Wadsak W. Pichler V, et al. Among authors: pfaff s. J Nucl Med. 2018 Sep;59(9):1350-1354. doi: 10.2967/jnumed.117.190793. Epub 2018 Jul 24. J Nucl Med. 2018. PMID: 30042159 Free article. Review.
Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-Pentixafor-PET/MRI.
Haug AR, Leisser A, Wadsak W, Mitterhauser M, Pfaff S, Kropf S, Wester HJ, Hacker M, Hartenbach M, Kiesewetter-Wiederkehr B, Raderer M, Mayerhoefer ME. Haug AR, et al. Among authors: pfaff s. Theranostics. 2019 May 27;9(12):3653-3658. doi: 10.7150/thno.31032. eCollection 2019. Theranostics. 2019. PMID: 31281504 Free PMC article.
191 results